Edition:
United States

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.88USD
24 Mar 2017
Change (% chg)

$-0.04 (-1.02%)
Prev Close
$3.92
Open
$3.94
Day's High
$3.97
Day's Low
$3.87
Volume
217,398
Avg. Vol
326,966
52-wk High
$7.49
52-wk Low
$2.98

AGEN.OQ

Chart for AGEN.OQ

About

Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to... (more)

Overall

Beta: 2.06
Market Cap(Mil.): $337.56
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  AGEN.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -1.46 -- --
ROI: -77.10 -2.56 13.01
ROE: -805.04 5.14 14.16

BRIEF-Incyte and Agenus amend collaboration agreement

* Incyte Corp - amended agreement converts ongoing GITR and ox40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs

Feb 14 2017

BRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus

* Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing Source text - http://bit.ly/2lpg9SS Further company coverage:

Feb 09 2017

BRIEF-QVT Financial reports 5.08 pct passive stake in Agenus

* QVT Financial Lp reports a 5.08 percent passive stake in Agenus Inc as of January 24, 2017 - sec filing Source text - http://bit.ly/2jHW6OQ Further company coverage:

Feb 03 2017

BRIEF-Agenus files for offering of up to 157,513 shares by selling stockholder

* Files for offering of up to 157,513 shares of co's common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2jIMpis) Further company coverage:

Jan 20 2017

BRIEF-Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

* Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine

Jan 17 2017

BRIEF-Agenus reports Q3 loss per share $0.47

* Agenus reports third quarter financial results and recent highlights

Oct 27 2016

More From Around the Web

Earnings vs. Estimates